FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Eom, Ki Seong ^a   Min, Woo Sung ^a   Kim, Hee Je ^a   Cho, Byung Sik ^a   Choi, Su Mi ^a   Lee, Dong Gun ^a   Lee, Seok ^a   Min, Chang Ki ^a   Kim, Yoo Jin ^a   Cho, Seok Goo ^a   Lee, Jong Wook ^a   Kim, Chun Choo ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

AML; Ara C; FLANG; Fludarabine; G CSF; Mitoxantrone; Refractory; Relapse

Indexed keywords

AMSACRINE; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ITRACONAZOLE; MELPHALAN; METHOTREXATE; MITOXANTRONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; LEUKEMIA RELAPSE; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; SEPSIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT REFUSAL; TREATMENT RESPONSE; WHOLE BODY RADIATION;

EID: 84655170246     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9653-6     Document Type: Article

References (29)

1. T Robak A Wrzesien-Kus 2002 The search for optimal treatment in relapsed and refractory acute myeloid leukemia Leuk Lymphoma 43 281 291 (Pubitemid 34211003)
2. CL Davis AZ Rohatiner J Lim 1993 The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period Br J Haematol 83 404 411 (Pubitemid 23080010)
3. V Liso P Iacopino G Avvisati 1996 Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Leukemia 10 1443 1452 (Pubitemid 26290323)
4. M Vignetti E Orsini MC Petti 1996 Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience Ann Oncol 7 933 938 (Pubitemid 26426268)
5. R Bassan T Lerede M Buelli 1998 A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia Haematologica 83 422 427 (Pubitemid 28299248)
6. AM Carella P Carlier E Pungolino 1993 Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA cooperative group Leukemia 7 196 199 (Pubitemid 23079227)
7. C Ferra JJ Berlanga D Gallardo 2000 Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia Leuk Lymphoma 39 583 590 (Pubitemid 32162396)
8. W Kern C Aul G Maschmeyer 1998 Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison Leukemia 12 1049 1055 (Pubitemid 28349799)
9. W Kern E Schleyer J Braess 2001 Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias Ann Hematol 80 334 339 (Pubitemid 32591083)
10. V Gandhi E Estey MJ Keating W Plunkett 1993 Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy J Clin Oncol 11 116 124 (Pubitemid 23059984)
11. W Plunkett V Gandhi P Huang 1993 Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies Semin Oncol 20 2 12 (Pubitemid 23333771)
12. A Tafuri M Andreeff 1990 Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro Leukemia 4 826 834
13. V Gandhi E Estey M Du B Nowak MJ Keating W Plunkett 1995 Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony- stimulating factor during therapy of acute myelogenous leukemia Clin Cancer Res 1 169 178
14. HS Park DW Kim CC Kim 1996 Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen-a prospective, cooperative multicenter study Semin Hematol 33 24 29 (Pubitemid 26367402)
15. WS Min HJ Kim Y Choi HY Jeong CC Kim 2007 Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients Hematol Oncol 25 76 83 (Pubitemid 46972834)
16. BD Cheson JM Bennett KJ Kopecky 2003 Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 21 4642 4649 (Pubitemid 46594039)
17. Lisa GS, T. N. ISCN 2005: An international system for human cytogenetic nomenclature (cytogenetic & genome research): S. Karger AG; 2005.
18. ML Slovak KJ Kopecky PA Cassileth 2000 Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern cooperative oncology group study Blood 96 4075 4083
19. LH Leopold R Willemze 2002 The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature Leuk Lymphoma 43 1715 1727 (Pubitemid 34874002)
20. S Stanisic M Kalaycio 2002 Treatment of refractory and relapsed acute myelogenous leukemia Expert Rev Anticancer Ther 2 287 295 (Pubitemid 34679484)
21. E Estey P Thall M Andreeff 1994 Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor J Clin Oncol 12 671 678
22. G Jackson P Taylor GM Smith 2001 A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation Br J Haematol 112 127 137 (Pubitemid 32151160)
23. E Felman V Gandhi W Plunkett 1992 Sequential administration of fludarabine, ara-C and mitoxantrone enhances topoisomerase II-DNA complex formation and has efficacy in acute leukemia Blood 80 Suppl 1 208a
24. V Heinemann D Murray R Walters RE Meyn W Plunkett 1988 Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine Cancer Chemother Pharmacol 22 205 210
25. D Milligan CK Wheatley JT Craig TJ Littlewood A Bennett 2004 Randomized comparison of FLA versus ADE with or without GCSF and with or without ATRA for high risk AML: results of the MRC AML-HR trial Hematologica 7 588a
26. X Thomas E Archimbaud 1997 Mitoxantrone in the treatment of acute myelogenous leukemia: a review Hematol Cell Ther 39 63 74
27. F Ferrara S Palmieri G Mele 2004 Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia Haematologica 89 998 1008 (Pubitemid 39049910)
28. Russell JA, Irish W, Balogh A, et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant;16:509-14.
29. GH Jackson 2004 Use of fludarabine in the treatment of acute myeloid leukemia Hematol J 5 Suppl 1 S62 S67